Analyst Price Target is $110.00
▲ +5,040.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for OncoSec Medical in the last 3 months. The average price target is $110.00, with a high forecast of $110.00 and a low forecast of $110.00. The average price target represents a 5,040.19% upside from the last price of $2.14.
Current Consensus is
The current consensus among 1 polled investment analysts is to hold stock in OncoSec Medical. This rating has held steady since April 2022, when it changed from a Buy consensus rating.
OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in Pennington, NJ.